ascopubs.org

Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.

Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. This is an ASCO Meeting ...
Cure Today

Short-Course Radiation Aids Survival in Older Patients With Glioblastoma

18F-DOPA PET-guided proton beam therapy improved overall survival in older glioblastoma patients, with a median OS of 13.1 months and no grade 4 adverse events. The hypofractionated regimen, completed ...
Business Wire

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during ...
FierceBiotech

AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol Myers ...
FierceBiotech

Sanofi phase 3 eczema win falls short of analyst expectations

A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% ...